Survey of the susceptibility of urinary isolates to antibacterial agents in 2003

Journal of Infection and Chemotherapy

Volumn 11, Issue 1, 2005, Pages 44-47

  Ishikawa, Kiyohito ^a   Hayakawa, Satoshi ^a   Miyakawa, Shinzaburo ^a   Kusaka, Mamoru ^a   Shiroki, Ryoichi ^a   Hoshinaga, Kiyotaka ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Antimicrobial susceptibility; Extended spectrum lactamase; Fluoroquinolone resistance strains; Urinary tract infection

Indexed keywords

ANTIINFECTIVE AGENT; BETA LACTAM DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TETRACYCLINE DERIVATIVE;

ANTIMICROBIAL ACTIVITY; BACTERIAL STRAIN; ENTEROCOCCUS; ESCHERICHIA COLI; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PENICILLIN RESISTANCE; POSTMARKETING SURVEILLANCE; PROTEUS; PSEUDOMONAS AERUGINOSA; REVIEW; SERRATIA MARCESCENS; SPECIES; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS EPIDERMIDIS; URINARY TRACT INFECTION;

EID: 15044343776     PISSN: 1341321X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10156-004-0356-9     Document Type: Article

References (15)

1. Stamm WE, Hooton TM. Management of urinary tract infections in adults. N Engl J Med 1993;329:1328-34.
2. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. 12th informational supplement M100-S12. Wayne: National Committee for Clinical Laboratory Standards; 2002.
3. Ishikawa K, Hayakawa S, Miyakawa S, Naide Y, Hoshinaga K. Survey of susceptibility of urinary isolates of bacterial species to antibacterial agents in 2002. Chemotherapy 2003;51:638-46.
4. Wang F, Zhu D, Hu F, Zhang Y. Surveillance of bacterial resistance among isolates in Shanghai in 1999. J Infect Chemother 2001;7:117-20.
5. Wang M, Tran JH, Jacoby GA, Zhang Y, Wang F, Hooper DC. Plasmid-mediated quinolone resistance in clinical isolates of Escherichia coli from Shanghai, China. Antimicrob Agents Chemother 2003;47:2242-8.
6. Lindgren PK, Karlsson A, Hughes D. Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections. Antimicrob Agents Chemother 2003;47:3222-32.
7. Said-Salim B, Mathema B, Kreiwirth BN. Community-acquired methicinin-resistant Staphylococcus aureus: an emerging pathogen. Infect Control Hosp Epidemiol 2003;24:451-5.
8. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S. et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-3.
9. Konno M, Arakawa Y. Domestic and foreign situation regarding changes in drug-resistant bacteria and the infections they cause. Chemotherapy (Tokyo) 2000;48:251-77.
10. Ishikawa K, Miyakawa S, Tanaka T, Naide Y, Shiroki R, Hoshinaga K. The trend and susceptibility to antibacterial agents of enterococcus species from urinary tract infection. Jpn J Urol 2003;95:25-34.
11. Ishikawa K, Hayakawa S, Katayama T, Hoshinaga K, Fukaya S, Torikai K, et al. Epidemiological study of vancomycin-resistant enterococcus isolated from a single medical university hospital in Japan. J Infect Chemother 2001;7:163-8.
12. Yoshida H, Bogaki M, Nakamura M, Nakamura S. Quinolone resistance determining region in the DNA gyrase gyr A gene of Escherichia coli. Antimicrob Agents Chemother 1990;34:1271-2.
13. Akasaka T, Tanaka Y, Sato K, Yamaguchi K. Detection of a quinolone-resistant gene (qnr) inplasmid. Chemotherapy (Tokyo) 2003;51(S-A):92.
14. Tsuji A, Kobayashi T, Oguri T, Yabuuchi E, Inoue M, Goto S. Current antimicrobial susceptibilities to Pseudomonas aeruginosa detected from clinical materials. Chemotherapy (Tokyo) 2003;51(S-A):99.
15. Wenzel RP, Sahm DF, Thornsberry C, Draghi DC, Jones ME, Karlowsky A. In vitro susceptibilities of gram-negative bacteria isolated from hospitalized patients in four European countries, Canada, and the United States in 2000-2001 to expanded-spectrum cephalosporins and comparator antimicrobials: implications for therapy. Antimicrob Agents Chemother 2003;47:3089-98.